Vitamin D is known not only for its importance for bone health but also for its biologic activities on many other organ systems. This is due to the presence of the
vitamin D receptor in various types of cells and tissues, including the skin, skeletal muscle, adipose tissue, endocrine pancreas, immune cells, and blood vessels. Experimental studies have shown that
vitamin D exerts several actions that are thought to be protective against coronavirus disease (COVID-19) infectivity and severity. These include the immunomodulatory effects on the innate and adaptive immune systems, the regulatory effects on the renin-angiotensin-aldosterone-system in the kidneys and the lungs, and the protective effects against endothelial dysfunction and
thrombosis. Prior to the
COVID-19 pandemic, studies have shown that
vitamin D supplementation is beneficial in protecting against risk of acquiring acute respiratory
viral infection and may improve outcomes in
sepsis and
critically ill patients. There are a growing number of data connecting
COVID-19 infectivity and severity with
vitamin D status, suggesting a potential benefit of
vitamin D supplementation for primary prevention or as an adjunctive treatment of
COVID-19. Although the results from most ongoing randomized clinical trials aiming to prove the benefit of
vitamin D supplementation for these purposes are still pending, there is no downside to increasing
vitamin D intake and having sensible sunlight exposure to maintain serum
25-hydroxyvitamin D at a level of least 30 ng/mL (75 nmol/L) and preferably 40 to 60 ng/mL (100-150 nmol/L) to minimize the risk of
COVID-19 infection and its severity.